Sign In
Buy PIRS
$13.60
+0 (+0%)
At Close: Mar 12, 2025
3 Biotechs That Will Crush the Bear
04:00pm, Friday, 11'th Mar 2022
Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
09:00pm, Friday, 04'th Mar 2022 The Motley Fool
Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
09:00pm, Friday, 04'th Mar 2022 The Motley Fool
Here''s why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
04:00pm, Friday, 04'th Mar 2022
Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates
04:05pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2021 Results - Earnings Call Transcript
01:12pm, Tuesday, 01'st Mar 2022
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2021 Results - Earnings Call Transcript
Pieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97M
12:18pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Pieris Pharmaceuticals press release (PIRS): FY GAAP EPS of -$0.71 beats by $0.17.Revenue of $31.41M (+7.1% Y/Y) beats by $5.97M.
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates
12:15pm, Tuesday, 01'st Mar 2022
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group?
08:05pm, Monday, 28'th Feb 2022 Benzinga
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Pieris Pharmaceuticals Inc (NASDAQ: PIRS ), Baidu Inc (NASDAQ: BIDU ) and Cronos Group Inc (NASDAQ: CRON ): Traders and investors will be watching for Pieris’s fourth-quarter earnings report, confirmed for Tuesday’s pre-market session. According to analyst consensus estimates, Pieris is expected to report an EPS loss of 3 cents on revenue of $2.45 million. Pieris reported in November an EPS loss of … Full story available on Benzinga.com
Pieris Pharmaceuticals Q4 2021 Earnings Preview
07:44pm, Monday, 28'th Feb 2022 Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.25 and the consensus…
Heska (HSKA) Tops Q4 Earnings and Revenue Estimates
02:25pm, Monday, 28'th Feb 2022 Zacks Investment Research
Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Biotechs That Will Soar Regardless of COVID-19
11:23pm, Thursday, 27'th Jan 2022 The Motley Fool
In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.
3 Biotechs That Will Soar Regardless of COVID-19
06:23pm, Thursday, 27'th Jan 2022
In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.
2 Risky Growth Stocks That Could Make You Filthy Rich
03:30pm, Sunday, 16'th Jan 2022 The Motley Fool
These two biotech stocks are set to report key clinical data later this year.
2 Risky Growth Stocks That Could Make You Filthy Rich
10:30am, Sunday, 16'th Jan 2022
These two biotech stocks are set to report key clinical data later this year.
